Intragenic mutations of the RUNX1 gene were preliminary reported in MDS, secondary and therapy-related AML, radiation exposed myelodysplastic syndrome (MDS) and AML [26–28]. This evidence concerns the gene RUNX1 and acute myeloid leukemia.